Whitfield Advises Vertex on $10 Billion Acquisition of Crinetics

Press Release   ·   06 July 2026

Overview

Vertex agreed to acquire Crinetics for approximately $10 billion of equity value, according to the source announcement about endocrine-disease medicines.

Offer economics

The proposed cash price was $85 per share, equivalent to approximately $8.8 billion after estimated acquired cash. Both boards approved the agreement unanimously.

Product portfolio

The source identifies paltusotine, marketed as PALSONIFY, and development candidate atumelnant among Crinetics' assets. These descriptions concern the announced acquisition, not treatment recommendations.

Timing and advisers

Completion was expected in the third quarter of 2026. Graham Robinson, Laura Knoll and Merric Kaufman are among the corporate advisers credited.